Bipolar Disorder

Chicago, IL

17 Bipolar Disorder Trials near Chicago, IL

Power is an online platform that helps thousands of Bipolar Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18 - 65

274 Participants Needed

KarXT for Mania

Chicago, Illinois
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18 - 65

274 Participants Needed

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18 - 65

300 Participants Needed

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2

200 Participants Needed

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

384 Participants Needed

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

220 Participants Needed

OLZ/SAM for Schizophrenia

Chicago, Illinois
This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:10 - 17

236 Participants Needed

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 60

524 Participants Needed

The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:16 - 35

180 Participants Needed

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:10 - 17

380 Participants Needed

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

256 Participants Needed

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17

310 Participants Needed

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

350 Participants Needed

This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

450 Participants Needed

This trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

72 Participants Needed

This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less cognitive/memory side effects (no memory side effects were noted in our prior studies for 500mA and 600mA) and thus is more favorable in terms of side effects compared to RUL conventional pulse amplitude ECT, while maintaining better anti-suicidal effect.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

30 Participants Needed

Why Other Patients Applied

"I have suffered from different mental health issues and have not had very good luck with finding what works best for me. My mental illness is seriously hurting my marriage and home life... I've been reading about new research treatments and think that they might work better than traditional treatments. Excited to try."

QQ
Bipolar Disorder PatientAge: 43

"I've been experiencing bipolar depression since I was a teenager and have tried many treatments that have not helped: SSRIs (Prozac), Wellbutrin, talk therapy. None worked. I've heard great things about ketamine therapy and would really like to try it. I'd like to access it through a clinical trial."

FM
Bipolar Disorder PatientAge: 38

"I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

EC
Bipolar Disorder PatientAge: 42

"I've been struggling with alcoholism and depression on-and-off for about 12 years. I have heard of people have good outcomes for various mental health issues after using psilocybin but would not be willing to try it without a doctor's care. So I'm applying to a trial. "

QJ
Depression PatientAge: 60

"Over 20 years, I've tried 6+ antidepressants and anti-anxiety meds to no avail. Cymbalta is the ONLY one that has ever made a difference (which I can use because I have bipolar 2, not 1) but it had some other side effects. I've been hesitant to try any trials, but also at a deadend of any relief. So, let's give it a shot."

ZJ
Bipolar Disorder PatientAge: 42

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Bipolar Disorder clinical trials in Chicago, IL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Bipolar Disorder clinical trials in Chicago, IL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Bipolar Disorder trials in Chicago, IL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Chicago, IL for Bipolar Disorder is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Chicago, IL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Bipolar Disorder medical study in Chicago, IL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Bipolar Disorder clinical trials in Chicago, IL?

Most recently, we added KarXT for Bipolar Disorder, KarXT for Bipolar Disorder and KarXT for Mania to the Power online platform.

Is there hope for people with bipolar?

Absolutely—bipolar disorder is very treatable: with mood-stabilizing medicines plus evidence-based talk therapy and a regular sleep–wake routine, more than 70 % of people achieve long symptom-free stretches and many return to work, school, and satisfying relationships. Sticking with treatment, watching for early warning signs, and using supports such as the Depression & Bipolar Support Alliance greatly increase those odds, so a full, meaningful life is a realistic goal rather than wishful thinking.

What is the first red flag of bipolar disorder?

There isn’t one universal “first” symptom, but the earliest red flag doctors see most often is a sudden decrease in the need for sleep—sleeping only a few hours yet feeling unusually energized and unable to shut your mind off. If this change lasts several days, especially when paired with racing thoughts, extra talkativeness, big ideas, or risky spending, it’s time to get a mental-health check-up because catching bipolar disorder early greatly improves treatment success.

What is the strongest medication for bipolar?

There isn’t a single “strongest” pill for bipolar disorder; doctors match the medicine to the phase and the person. For acute mania, lithium or valproate often combined with an atypical antipsychotic (e.g., quetiapine, olanzapine) typically works fastest; for bipolar depression, lamotrigine or quetiapine lead, and for long-term prevention lithium remains the gold standard when tolerated. The best regimen is the one that controls your symptoms with acceptable side effects, so choice and dose are always individualized by a psychiatrist who can monitor blood levels and overall health.

Why do people with bipolar go off their meds?

People stop bipolar medication for three main clusters of reasons: 1) medication factors—unpleasant side-effects (weight gain, tremor, mental “fog”) or complex dosing that make daily use feel worse than the illness; 2) illness factors—mood swings that create denial (“I’m fine now”) or the euphoric energy of mania that makes pills seem unnecessary or even unwanted; and 3) practical/social factors—cost, stigma, substance use, or a poor fit with the prescribing clinician. Recognizing which cluster is at play helps patients, families, and doctors tailor solutions—whether that’s adjusting the drug, adding psycho-education or reminders, or improving access—rather than assuming the person is simply being “non-compliant.”

What is unhealthy coping for bipolar people?

With bipolar disorder, “unhealthy coping” is anything you do to feel better in the moment that ends up disrupting one of three stabilisers: (1) your medication plan, (2) a regular sleep-and-daily routine, or (3) clear, substance-free judgement. Habits that break those stabilisers—skipping meds, drinking or using drugs, staying up late gaming or doom-scrolling, isolating yourself, or chasing risky thrills like overspending—tend to push mood swings harder and make recovery slower; replacing them with steady sleep, sober living, social support, and professional treatment keeps the illness on a shorter, safer leash.

Can untreated bipolar disorder lead to psychosis?

Yes. When bipolar mood swings are allowed to build unchecked, they can become so intense that a person loses touch with reality—research shows psychosis occurs in roughly 6 in 10 people with bipolar I and 2 in 10 with bipolar II, usually during extreme mania or depression. Staying on mood-stabilizing medication, keeping a regular sleep schedule, and seeking immediate care if hallucinations or fixed false beliefs emerge greatly reduce this risk and shorten episodes.

How does a person with bipolar think?

Thinking in bipolar disorder depends on the phase: during mania the mind races with big, fast ideas and bold confidence, while during depression thoughts slow down, dwell on negatives, and decision-making feels heavy; between episodes most people return to their usual, clear thinking, though some lingering trouble with focus or memory can remain. Recognising these predictable swings—and getting help early with medication, therapy, sleep, and support—makes it easier to manage symptoms and respond to a loved one with understanding instead of frustration.

Which hormone causes bipolar disorder?

No single hormone causes bipolar disorder; it is a brain-based mood condition shaped by genetics, life stress, and how different body systems interact. Shifts in thyroid hormone, the stress hormone cortisol, or female sex hormones can nudge symptoms better or worse—which is why doctors often check thyroid levels and watch times like postpartum or menopause—but fixing those levels alone doesn’t cure the disorder.

What is end stage bipolar disorder?

“End-stage” (or late-stage) bipolar disorder is an informal term doctors sometimes use for people whose illness has become chronic, treatment-resistant, and functionally disabling: mood swings remain frequent or severe despite multiple therapies, and there may be memory problems, physical health issues, and difficulty living independently. While this stage signals a need for more intensive care—such as combination medications, electro-convulsive or other neuromodulation therapies, cognitive/functional rehabilitation, and strong social supports—it is not a hopeless diagnosis; working closely with a mental-health team can still reduce symptoms and improve quality of life.

What current research is being done for bipolar disorders?

Today’s bipolar-disorder research falls into five main streams: scientists are mapping hundreds of risk and “treatment-response” genes, testing rapid-acting medicines such as ketamine and psilocybin, refining brain-stimulation tools like transcranial magnetic stimulation, using smartphone and wearable data to predict mood swings and stabilize sleep-wake cycles, and running early-intervention trials in high-risk teens and young adults. Together, these projects aim not just to explain why bipolar illness occurs but to deliver faster, more personalized treatments and even prevent new episodes before they start.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security